The start of the new year doesn’t seem to have dulled the zeal of Pfizer’s global cost-cutting campaign, which has already left hundreds of jobs in its wake.

Come mid-February, Pfizer will lay off some 52 employees at a facility in South San Francisco, according to a recent Worker Adjustment and Retraining Notification Act (WARN) alert.

It’s the end of an era as the world’s first commercial biologics plant—once home to a secretive project dubbed “Orange Marmalade”—turns out the lights.

After years of planning, Genentech is winding down operations at its production facility in South San Francisco, the company told Fierce Pharma. The site wrapped up its final production runs several weeks back and is now in the decommissioning phase, which will take some six to 12 months.

The mRNA biotech announced Friday that it will be opening two new offices in South San Francisco and Seattle this year. Moderna chief information officer Brad Miller told Endpoints News the Seattle office is slated to open April 4.

After a two-year hiatus, the JPM Healthcare Conference returned to downtown San Francisco, CA this week as intense rainstorms swept through the area.

Johnson & Johnson on Tuesday unveiled a new research and development facility in San Francisco, aiming to grow its presence in one of the top biotechnology hubs in the U.S.

As the demand for new drugs is growing, it's challenging the biotech industry to re-think its approach to making them for clinical trials. South San Francisco's Genentech opened a new lab today that, not only accelerates the process, but also saves water and energy.

Astellas Pharma has announced plans to build an integrated biotech facility at 480 Forbes Boulevard, South San Francisco. The new 154,000-square-foot facility will function as a West Coast center for Astella Pharma to focus on research, innovation and commercial operations across program and corporate areas.

Astellas Pharma Inc. plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center. The new 154,000-sq.-ft. building at 480 Forbes Boulevard will allow for the co-location of several Astellas business units and functions currently located independently throughout the San Francisco area.

In yet another opioid settlement, Teva has agreed to pay $24.8 million over 13 years, plus provide $20 million worth of Narcan over 10 years, to resolve its share of the litigation in San Francisco. Meanwhile, AbbVie's Allergan unit will pay $13 million to escape the claims.